242 related articles for article (PubMed ID: 30849944)
41. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
42. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
43. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
44. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
[TBL] [Abstract][Full Text] [Related]
45. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
[TBL] [Abstract][Full Text] [Related]
46. Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
Camp NJ; Madsen MJ; Herranz J; Rodríguez-Lescure Á; Ruiz A; Martín M; Bernard PS
Breast Cancer Res Treat; 2019 May; 175(1):129-139. PubMed ID: 30673970
[TBL] [Abstract][Full Text] [Related]
47. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.
Kensler KH; Sankar VN; Wang J; Zhang X; Rubadue CA; Baker GM; Parker JS; Hoadley KA; Stancu AL; Pyle ME; Collins LC; Hunter DJ; Eliassen AH; Hankinson SE; Tamimi RM; Heng YJ
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):798-806. PubMed ID: 30591591
[TBL] [Abstract][Full Text] [Related]
48. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
Kimbung S; Kovács A; Danielsson A; Bendahl PO; Lövgren K; Frostvik Stolt M; Tobin NP; Lindström L; Bergh J; Einbeigi Z; Fernö M; Hatschek T; Hedenfalk I
Oncotarget; 2015 Oct; 6(32):33306-18. PubMed ID: 26375671
[TBL] [Abstract][Full Text] [Related]
49. Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at
Madsen MJ; Knight S; Sweeney C; Factor R; Salama M; Stijleman IJ; Rajamanickam V; Welm BE; Arunachalam S; Jones B; Rachamadugu R; Rowe K; Cessna MH; Thomas A; Kushi LH; Caan BJ; Bernard PS; Camp NJ
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):644-652. PubMed ID: 29650789
[No Abstract] [Full Text] [Related]
50. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
51. Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.
Hurson AN; Hamilton AM; Olsson LT; Kirk EL; Sherman ME; Calhoun BC; Geradts J; Troester MA
Breast Cancer Res Treat; 2023 May; 199(1):147-154. PubMed ID: 36892725
[TBL] [Abstract][Full Text] [Related]
52. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
53. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
54. Determining breast cancer histological grade from RNA-sequencing data.
Wang M; Klevebring D; Lindberg J; Czene K; Grönberg H; Rantalainen M
Breast Cancer Res; 2016 May; 18(1):48. PubMed ID: 27165105
[TBL] [Abstract][Full Text] [Related]
55. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
56. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
57. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
[TBL] [Abstract][Full Text] [Related]
58. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
